The agreement between Canada and Europe over the Patent term extension for Pharma related Patents is now approved.
It took many years of negotiations and on October 28, 2016, finally it got a green signal from Europe and Canada govt. All 28 European Union members signed the agreement which was later signed by Canadian Prime Minister Justin Trudeau on October 30, 2016.
This historic agreement promises, inter alia, to bring important changes to intellectual property protection for pharmaceutical patentees in Canada – such as Patent term extension and an end to dual litigation, which will bring Canada more in line with European practice.
On October 31, 2016 – the day after Prime Minister Trudeau signed CETA – the Canadian Government introduced Bill C-30 in Parliament, An Act to implement the Comprehensive Economic and Trade Agreement between Canada and the European Union and its Member States. Introducing Bill C-30 is the first step towards implementing CETA in Canadian law and as such, it proposes several changes to the Canadian Patent & Food and Drug Act as they pertain to protection of innovative pharmaceuticals.
Original Article: https://goo.gl/YVN9fv